Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OVID 
Ovid Therapeutics Inc (OVID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OVID (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.4
1 Year Target Price $3.4
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 137.42% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.89M USD | Price to earnings Ratio - | 1Y Target Price 3.4 |
Price to earnings Ratio - | 1Y Target Price 3.4 | ||
Volume (30-day avg) 6 | Beta 0.21 | 52 Weeks Range 0.24 - 1.47 | Updated Date 08/29/2025 |
52 Weeks Range 0.24 - 1.47 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.16 | Actual -0.06 |
Profitability
Profit Margin - | Operating Margin (TTM) -80.88% |
Management Effectiveness
Return on Assets (TTM) -26.71% | Return on Equity (TTM) -52.77% |
Valuation
Trailing PE - | Forward PE 1.79 | Enterprise Value 64638892 | Price to Sales(TTM) 13.36 |
Enterprise Value 64638892 | Price to Sales(TTM) 13.36 | ||
Enterprise Value to Revenue 9.72 | Enterprise Value to EBITDA -0.69 | Shares Outstanding 71109504 | Shares Floating 59524352 |
Shares Outstanding 71109504 | Shares Floating 59524352 | ||
Percent Insiders 16.31 | Percent Institutions 34.69 |
Upturn AI SWOT
Ovid Therapeutics Inc
Company Overview
History and Background
Ovid Therapeutics Inc. was founded in 2003. It's a biopharmaceutical company focused on developing therapies for rare neurological diseases. The company has shifted its focus and undergone changes in its pipeline over the years.
Core Business Areas
- Neurology: Focuses on developing and commercializing therapies for rare neurological disorders. Currently, they have minimal active programs after pipeline adjustments.
Leadership and Structure
The company has a board of directors and an executive leadership team responsible for strategic direction and operations. Specific details can be found on their investor relations site.
Top Products and Market Share
Key Offerings
- Gabapentin ER: Ovid Therapeutics Inc. acquired the U.S. rights to Gabapentin ER in 2023 from TRx Pharmaceutical, LLC.. Competitors include generic drug manufacturers of gabapentin.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high risk, high reward, and extensive regulatory oversight. The focus is on developing and commercializing innovative therapies for unmet medical needs.
Positioning
Ovid Therapeutics is positioned as a company focused on rare neurological diseases. They are in the process of repositioning their business after key drug failures.
Total Addressable Market (TAM)
The TAM for rare neurological diseases is significant, estimated to be in the billions of dollars. Ovid's positioning depends on the successful development and commercialization of their current and future pipeline.
Upturn SWOT Analysis
Strengths
- Acquired assets
- Expertise in rare neurological diseases (historical)
- Experienced management team
Weaknesses
- Limited pipeline
- History of clinical trial failures
- Financial instability
- Small market capitalization
Opportunities
- Potential for successful drug development and commercialization
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger company
- Expanding into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other pharmaceutical companies
- Funding challenges
- Patent expiration
Competitors and Market Share
Key Competitors
- ZGNX
- AVXL
- GRTS
Competitive Landscape
Ovid faces strong competition from established pharmaceutical companies and emerging biotech firms. Their success depends on differentiating their therapies and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Ovid's historical growth has been erratic due to clinical trial setbacks and pipeline adjustments.
Future Projections: Future growth is contingent on successful drug development and commercialization. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include refocusing R&D efforts and exploring potential strategic partnerships.
Summary
Ovid Therapeutics is a struggling biopharmaceutical company undergoing significant transformation. Its history is marked by clinical setbacks, but it is attempting to pivot with new assets. The company needs to demonstrate successful drug development to ensure its long-term viability. Financial stability and market competition remain key challenges for Ovid Therapeutics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made after conducting thorough research and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ovid Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-05-05 | CEO & Chairman Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.ovidrx.com |
Full time employees 23 | Website https://www.ovidrx.com | ||
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.